Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

squamous cell carcinoma cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (7) Amyloid-β (1) Antibiotic (1) Apoptosis (21) Autophagy (15) Bacterial (2) Bcl-2 Family (2) c-Met/HGFR (7) c-Myc (1) Calcium Channel (1) Caspase (4) CD47 (1) CDK (2) Checkpoint Kinase (Chk) (1) COX (2) Deubiquitinase (1) DNA Alkylator/Crosslinker (1) Drug Metabolite (1) DYRK (2) EGFR (11) Endogenous Metabolite (3) ERK (2) Glycosidase (2) Histone Methyltransferase (1) HSP (1) HSV (5) Huntingtin (1) IAP (2) IFNAR (1) JAK (1) Ligands for E3 Ligase (1) MAP3K (1) MDM-2/p53 (1) MEK (1) Mitochondrial Metabolism (1) MMP (1) mTOR (1) Necroptosis (1) NF-κB (3) Orphan Receptor (1) p38 MAPK (6) Parasite (2) PARP (1) PD-1/PD-L1 (2) Phospholipase (1) Photosensitizer (1) PI3K (1) PKC (1) PROTACs (2) Proteasome (1) RAR/RXR (2) Reactive Oxygen Species (2) SARS-CoV (5) Sirtuin (2) STAT (1) TNF Receptor (1) Toll-like Receptor (TLR) (5) Transmembrane Glycoprotein (1) Tyrosinase (1)
By Research Areas:	Cancer (65) Cardiovascular Disease (3) Infection (8) Inflammation/Immunology (11) Metabolic Disease (4) Neurological Disease (4)

By Targets:

Akt (7)

Amyloid-β (1)

Antibiotic (1)

Apoptosis (21)

Autophagy (15)

Bacterial (2)

Bcl-2 Family (2)

c-Met/HGFR (7)

c-Myc (1)

Calcium Channel (1)

Caspase (4)

CD47 (1)

CDK (2)

Checkpoint Kinase (Chk) (1)

COX (2)

Deubiquitinase (1)

DNA Alkylator/Crosslinker (1)

Drug Metabolite (1)

DYRK (2)

EGFR (11)

Endogenous Metabolite (3)

ERK (2)

Glycosidase (2)

Histone Methyltransferase (1)

HSP (1)

HSV (5)

Huntingtin (1)

IAP (2)

IFNAR (1)

JAK (1)

Ligands for E3 Ligase (1)

MAP3K (1)

MDM-2/p53 (1)

MEK (1)

Mitochondrial Metabolism (1)

MMP (1)

mTOR (1)

Necroptosis (1)

NF-κB (3)

Orphan Receptor (1)

p38 MAPK (6)

Parasite (2)

PARP (1)

PD-1/PD-L1 (2)

Phospholipase (1)

Photosensitizer (1)

PI3K (1)

PKC (1)

PROTACs (2)

Proteasome (1)

RAR/RXR (2)

Reactive Oxygen Species (2)

SARS-CoV (5)

Sirtuin (2)

STAT (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (5)

Transmembrane Glycoprotein (1)

Tyrosinase (1)

By Research Areas:

Cancer (65)

Cardiovascular Disease (3)

Infection (8)

Inflammation/Immunology (11)

Metabolic Disease (4)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor VISTA BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99461

Barecetamab ISU-104	EGFR	Cancer
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .

HY-17473

Embelin 4 Publications Verification Embelic acid; Emberine; NSC 91874	IAP NF-κB Apoptosis Autophagy	Cancer
Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC₅₀=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .

HY-P99208

Lirilumab 2 Publications Verification IPH2102	Transmembrane Glycoprotein	Cancer
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .

HY-119198

NSC745885	Apoptosis Histone Methyltransferase	Cancer
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple?cancer?cell lines but not normal cells.?NSC745885 is an effective?down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced?bladder?and oral squamous cell carcinoma (OSCC) cancers .

HY-149677

ZK53	Mitochondrial Metabolism	Cancer
ZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP) (EC₅₀: 1.37?μM for α-casein hydrolysis by HsClpP). ZK53 is is inactive toward bacterial ClpP proteins. ZK53 induces apoptosis in H1703, H520 and SK-MES-1 cells. ZK53 induces dysregulation of mitochondrial functions in lung squamous cell carcinoma (LUSC) cells. ZK53 inhibits tumor growth in H1703 xenograft mouse model .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-155785

MTP	Apoptosis Autophagy Reactive Oxygen Species JAK	Cancer
MTP is a PKM2 inhibitor. MTP induces cancer cell apoptosis by modulating caspase-3 activation. MTP induces autophagy and increases ROS generation. MTP also inhibits JAK2 signaling. MTP can be used for research of oral squamous cell carcinoma .

HY-106364

Peplomycin Bleomycin PEP; Pepleomycin	Antibiotic	Cancer
Peplomycin (Bleomycin PEP; Pepleomycin) is an antibiotic analogue of Bleomycin (HY-108345), with high antitumor effect and less pulmonary toxicity. Peplomycin induce apoptosis in oral squamous carcinoma cell line SSCKN cells and pulmonary fibrosis in rats .

HY-N12960

Artobiloxanthone	Apoptosis Bcl-2 Family Caspase COX MMP STAT	Cancer
Artobiloxanthone (Compound AA3) exhibits antitumor activity, particularly against oral squamous cell carcinoma (OSCC). Artobiloxanthone inhibits Akt/mTOR pathway and STAT3 pathway, inhibits proliferation of SAS and T.Tn (with IC₅₀ of 11 and 22 μM), and inhibits the cancer cell migration. Artobiloxanthone arrests cell cycle at S phase, and induces apoptosis in OSCC cells through activation of caspase 3/9 .

HY-17473R

Embelin (Standard)	IAP NF-κB Apoptosis Autophagy	Cancer
Embelin (Standard) is the analytical standard of Embelin. This product is intended for research and analytical applications. Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC50=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .

HY-119906

Conglobatin FW-04-806	HSP Apoptosis	Cancer
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-111458

GSK2643943A 5 Publications Verification	Deubiquitinase	Cancer
GSK2643943A is a deubiquitinating enzyme (DUB) inhibitor targeting USP20. GSK2643943A has affinity with an IC₅₀ of 160 nM for USP20/Ub-Rho. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC) .

HY-12204

PFK-015 3 Publications Verification	Autophagy	Metabolic Disease Inflammation/Immunology Cancer
PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC₅₀ value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC₅₀ value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC) .

HY-B0986

Hexylresorcinol 4-Hexylresorcinol	Parasite Bacterial Apoptosis Glycosidase Endogenous Metabolite	Infection Metabolic Disease Cancer
Hexylresorcinol (4-Hexylresorcinol) is a natural compound found in plants with antimicrobial, anthelmintic, antiseptic and antitumor activities. Hexylresorcinol can induce apoptosis in squamous carcinoma cells. Hexylresorcinol is a reversible and noncompetitive inhibitor of α-glucosidase. Hexylresorcinol has protective effects against oxidative DNA damage .

HY-P99032

Monalizumab 3 Publications Verification IPH2201	Checkpoint Kinase (Chk) IFNAR	Inflammation/Immunology Cancer
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .

HY-B0986R

Hexylresorcinol (Standard)	Parasite Bacterial Apoptosis Glycosidase Endogenous Metabolite	Infection Metabolic Disease Cancer
Hexylresorcinol (Standard) is the analytical standard of Hexylresorcinol. This product is intended for research and analytical applications. Hexylresorcinol (4-Hexylresorcinol) is a natural compound found in plants with antimicrobial, anthelmintic, antiseptic and antitumor activities. Hexylresorcinol can induce apoptosis in squamous carcinoma cells. Hexylresorcinol is a reversible and noncompetitive inhibitor of α-glucosidase. Hexylresorcinol has protective effects against oxidative DNA damage .

HY-114594

Khusimol	Others	Others
Khusimol is a compound used in chemotherapy for oral squamous cell carcinoma.

HY-N8380

(-)-Latifolin	Apoptosis Autophagy PI3K Necroptosis	Cardiovascular Disease Inflammation/Immunology Cancer
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

HY-N12760

Lobophorin CR-2	Others	Cancer
Lobophorin CR-2 is a lobophorin congener which induces UPR-associated gene expression, inhibits oral squamous cell carcinoma cell growth, and causes UPR-dependent cell death in MEF cells .

HY-N11050

Xerophilusin B	Apoptosis	Cancer
Xerophilusin B, an anticancer agent isolated from Isodon xerophilus, exhibits antiproliferative effects on esophageal squamous cell carcinoma (ESCC) cell lines, induces G2/M cell cycle arrest, and mediates apoptosis .

HY-19909A

NRC-2694-A	EGFR	Cancer
NRC-2694-A is an orally effective EGFR tyrosine kinase inhibitor. NRC-2694-A can be used in the study of malignant squamous cell carcinoma (HNSCC) .

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-126324

IV-23	Apoptosis	Cancer
IV-23 (Compound 20) is a potent Noxa mediated apoptosis inducer, and it is a promising anticancer agent with potential. IV-23 inhibits cell growths in vitro and in vivo, reduces colony formation, arrests cell cycle at M phase, and induces esophageal squamous cell carcinoma (ESCC) .

HY-151934

ERK-IN-6	Apoptosis	Cancer
ERK-IN-6 (compound 6g) is an potent anti-proliferation agent against esophageal squamous cell carcinoma (ESCC). ERK-IN-6 induces cell apoptosis via ERK pathway. ERK-IN-6 can be used for the research of ESCC .

HY-W342604

N-Acetylputrescine NAP	Endogenous Metabolite	Neurological Disease Cancer
N-Acetylputrescine (NAP) is an endogenous metabolite widely present in animals and plants. N-Acetylputrescine can be used as a biomarker for lung squamous cell carcinoma (SCCL) and Parkinson's disease (PD) for disease diagnosis .

HY-N0746

Oxysophocarpine 4 Publications Verification	Others	Cancer
Oxysophocarpine is an alkaloid extracted from Sophora alopecuroides.?Oxysophocarpine has neuroprotective and anti-nociceptive effects on the central and peripheral nervous systems . Oxysophocarpine inhibits the?growth?and?metastasis?of ?oral?squamous?cell?carcinoma?(OSCC) .

HY-N3665

Cyclocommunol	Tyrosinase	Cancer
Cyclocommunol is a prenylflavonoid with antityrosinase and antiplatelet activitie, can be solated from breadfruit. Cyclocommunol exerts anti-tumor activity and inhibits the growth of human hepatoma and gastric cancer cells with IC₅₀ values between 16 and 80 µM. Cyclocommunol shows proapoptotic effect on oral squamous cell carcinoma (OSCC) .

HY-111208

CCT129957	Phospholipase	Cancer
CCT129957 is an indole derivative and a potent phospholipase C-γ (PLC-γ) inhibitor with an IC₅₀ of ~3 μM and a GC₅₀ of 15 μM. CCT129957 inhibits Ca ²⁺ release in squamous carcinoma cells at ~15 μM .

HY-144614

JH-XVII-10	DYRK Apoptosis	Neurological Disease Cancer
JH-XVII-10 is a potent, selective and orally active DYRK1A and DYRK1B inhibitor with IC₅₀s of 3 nM and 5 nM for DYRK1A and DYRK1B, respectively. JH-XVII-10 shows antitumor efficacy in neck squamous cell carcinoma (HNSCC) cell lines .

HY-131649

Compound C108	Others	Cancer
Compound C108 is a G3BP2 inhibitor. Compound C108 also targeted stress granule-associated proteins and Gtpase-activating protein (SH3 domain) binding protein 2. Compound C108 potently inhibits esophageal squamous cell carcinoma (ESCC) cell metastasis .

HY-108527

CD1530	RAR/RXR	Cancer
CD1530 is a selective RARγ agonist with an K_d of 150 nM . CD1530 has been used in combination with bexarotene to inhibit oral carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide in a mouse model of human oral-cavity and esophageal squamous-cell carcinoma .

HY-114338A

Dalpiciclib hydrochloride SHR-6390 hydrochloride	CDK	Cancer
Dalpiciclib (SHR-6390) hydrochloride is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4 nM and 9.9 nM, respectively . Dalpiciclib hydrochloride shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .

HY-N0746R

Oxysophocarpine (Standard)	Others	Cancer
Oxysophocarpine (Standard) is the analytical standard of Oxysophocarpine. This product is intended for research and analytical applications. Oxysophocarpine is an alkaloid extracted from Sophora alopecuroides. Oxysophocarpine has neuroprotective and anti-nociceptive effects on the central and peripheral nervous systems . Oxysophocarpine inhibits the growth and metastasis of oral squamous cell carcinoma (OSCC) .

HY-114338

Dalpiciclib SHR-6390	CDK	Cancer
Dalpiciclib (SHR-6390) is an orally active and highly selective inhibitor of CDK4 and 6 with IC₅₀ values of 12.4?nM and 9.9?nM, respectively . Dalpiciclib shows antitumor activity against breast cancer and esophageal squamous cell carcinoma .

HY-119272

EF24 1 Publications Verification	ERK Caspase	Cancer
EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK .

HY-144617

JH-XIV-68-3	DYRK	Cancer
JH-XIV-68-3 is a selective macrocyclic inhibitor of DYRK1A/B. JH-XIV-68-3 displays selectivity for DYRK1A and close family member DYRK1B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines .

HY-P99715

Losatuxizumab ABT-806	EGFR	Cancer
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC₅₀s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR ^C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .

HY-17616

Ingenol disoxate LEO 43204	Drug Metabolite	Others
Ingenol disoxate (LEO 43204) is a drug metabolite, that exhibits potential in ameliorating actinic keratosis .

HY-15673

KP372-1 2 Publications Verification	Akt Reactive Oxygen Species Apoptosis	Cancer
KP372-1 is an Akt inhibitor that inhibits proliferation and induces apoptosis and anoikis. KP372-1 is also an NQO1 redox cycling agent that causes DNA damage (including DNA breakage) by generating ROS. KP372-1 can be used in cancer research (such as head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer) .

HY-114906

SIRT1/2/3-IN-2	Sirtuin	Cancer
SIRT1/2/3-IN-2 (compound 9) is a potent SIRT inhibitor, with inhibition rates of 27%, 72%, and 71% targeting SIRT1, SIRT2, and SIRT3, respectively, at 200 μM. SIRT3 is a potential tumor suppressor or promoter, and its increased transcription may be associated with lymph node-positive breast cancer and oral squamous cell carcinoma .

HY-P99406A

Petosemtamab (FUT8-KO)	EGFR	Cancer
Petosemtamab (FUT8-KO) is a knockout version of petosemtamab for the fucosyltransferase 8 gene (FUT8). Petosemtamab (HY-P99406) is an anti-EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .

HY-B0023

Azelnidipine 2 Publications Verification CS 905	Calcium Channel MEK	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Azelnidipine (CS 905) is a dihydropyridine calcium channel blocker that is effective orally. Azelnidipine inhibits the intracellular calcium ion flow and lower blood pressure by selectively blocking L-type calcium channel on the membrane of vascular smooth muscle. Azelnidipine inhibits esophageal squamous cell carcinoma proliferation by targeting MEK1/2. Azelnidipine also has anti-inflammatory, antioxidant and neuroprotective effects .

HY-10261

Afatinib Maximum Cited Publications 64 Publications Verification BIBW 2992	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-10261A

Afatinib dimaleate Maximum Cited Publications 64 Publications Verification BIBW 2992MA2	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-10261D

Afatinib oxalate BIBW 2992 oxalate	EGFR Autophagy Apoptosis c-Met/HGFR Akt	Cancer
Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR ^wt, EGFR ^L858R, EGFR ^L858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-P1823

C-Reactive Protein (CRP) (174-185)	Akt mTOR Caspase	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma .

HY-169135

PROTAC 20S proteasome subunit β5 degrader 2	PROTACs Proteasome	Cancer
PROTAC 20S proteasome subunit β5 degrader 2 is a PROTAC degrader for 20S proteasome subunit β5, with a DC₅₀ of 0.16 μM. PROTAC 20S proteasome subunit β5 degrader 2 inhibits the proliferation of cancer cell FaDu with IC₅₀ of 0.23 μM. PROTAC 20S proteasome subunit β5 degrader 2 exhibits antitumor efficacy in mice models . (Pink: Ligand for target protein (HY-10227); Blue: Ligand for E3 ligase (HY-103596); Black: Linker (HY-Y1760))

HY-10261R

Afatinib (Standard)	EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK	Cancer
Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer .

HY-136780

SEN177	Amyloid-β Apoptosis CD47 Huntingtin	Neurological Disease Cancer
SEN177 is an orally effect glutamine cyclase (QC) inhibitor. The K_i of SEN177 for human glutamine cyclase (hQC) is 20 nM, and the IC₅₀ is 13 nM. SEN177 interferes with the interaction between CD47 and SIRRPα, and has anti-tumor activity. SEN177 reduces aggregation and apoptosis caused by HTT mutation in Huntington model, and can be used in the study of neurodegenerative diseases .

HY-149913

NR2F1 agonist 1	Orphan Receptor Others	Cancer
NR2F1 agonist 1, a nuclear receptor NR2F1 agonist, specifically activates dormancy programs in malignant cells. NR2F1 agonist 1 up-regulates NR2F1 and downstream target genes that regulate dormancy. NR2F1 agonist 1 induces neural crest-like and growth suppression in head and neck squamous cell carcinoma (HNSCC) via NR2F1 activation. NR2F1 agonist 1 inhibits tumor growth in a mouse primary tumor model .

Cat. No.	Product Name	Target	Research Area

HY-P1823

C-Reactive Protein (CRP) (174-185)	Akt mTOR Caspase	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma .

HY-P5930

HOXB7 8–25 MDM2 32-46	Ligands for E3 Ligase	Cancer
HOXB7 8–25 (MDM2 32-46) is an MDM2-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 ⁺ T cell responses .

Cat. No.	Product Name	Target	Research Area